» Articles » PMID: 9650932

Algorithmic Approach to High-throughput Molecular Screening for Alpha Interferon-resistant Genotypes in Hepatitis C Patients

Overview
Specialty Microbiology
Date 1998 Jul 3
PMID 9650932
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

This study was designed to analyze the feasibility and validity of using Cleavase Fragment Length Polymorphism (CFLP) analysis as an alternative to DNA sequencing for high-throughput screening of hepatitis C virus (HCV) genotypes in a high-volume molecular pathology laboratory setting. By using a 244-bp amplicon from the 5' untranslated region of the HCV genome, 61 clinical samples received for HCV reverse transcription-PCR (RT-PCR) were genotyped by this method. The genotype frequencies assigned by the CFLP method were 44.3% for type 1a, 26.2% for 1b, 13.1% for type 2b, and 5% type 3a. The results obtained by nucleotide sequence analysis provided 100% concordance with those obtained by CFLP analysis at the major genotype level, with resolvable differences as to subtype designations for five samples. CFLP analysis-derived HCV genotype frequencies also concurred with the national estimates (N. N. Zein et al., Ann. Intern. Med. 125:634-639, 1996). Reanalysis of 42 of these samples in parallel in a different research laboratory reproduced the CFLP fingerprints for 100% of the samples. Similarly, the major subtype designations for 19 samples subjected to different incubation temperature-time conditions were also 100% reproducible. Comparative cost analysis for genotyping of HCV by line probe assay, CFLP analysis, and automated DNA sequencing indicated that the average cost per amplicon was lowest for CFLP analysis, at $20 (direct costs). On the basis of these findings we propose that CFLP analysis is a robust, sensitive, specific, and an economical method for large-scale screening of HCV-infected patients for alpha interferon-resistant HCV genotypes. The paper describes an algorithm that uses as a reflex test the RT-PCR-based qualitative screening of samples for HCV detection and also addresses genotypes that are ambiguous.

Citing Articles

Most common genotypes and risk factors for HCV in Gaza strip: a cross sectional study.

Ayesh B, Zourob S, Abu-Jadallah S, Shemer-Avni Y Virol J. 2009; 6:105.

PMID: 19607718 PMC: 2716328. DOI: 10.1186/1743-422X-6-105.


Vertical transmission of Chlamydia trachomatis in Chongqing China.

Yu J, Wu S, Li F, Hu L Curr Microbiol. 2009; 58(4):315-20.

PMID: 19123031 DOI: 10.1007/s00284-008-9331-5.


Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes.

Schroter M, Zollner B, Schafer P, Landt O, Lass U, Laufs R J Clin Microbiol. 2002; 40(6):2046-50.

PMID: 12037062 PMC: 130695. DOI: 10.1128/JCM.40.6.2046-2050.2002.


Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method.

Casadei S, Cortesi L, Pensotti V, Radice P, Pierotti M, Amadori D Br J Cancer. 2001; 85(6):845-9.

PMID: 11556835 PMC: 2375072. DOI: 10.1054/bjoc.2001.1988.


Principles and applications of methods for DNA-based typing of microbial organisms.

Olive D, Bean P J Clin Microbiol. 1999; 37(6):1661-9.

PMID: 10325304 PMC: 84917. DOI: 10.1128/JCM.37.6.1661-1669.1999.

References
1.
Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B . Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis. 1997; 29(1):17-22. DOI: 10.3109/00365549709008658. View

2.
Lau J, Mizokami M, Kolberg J, Davis G, Prescott L, Ohno T . Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis. 1995; 171(2):281-9. DOI: 10.1093/infdis/171.2.281. View

3.
Yuki N, Hayashi N, Mita E, Hagiwara H, Ohkawa K, Katayama K . Hepatitis C virus replicative levels and efficiency of genotyping by specific PCR and antibody assay. J Clin Microbiol. 1997; 35(5):1184-9. PMC: 232726. DOI: 10.1128/jcm.35.5.1184-1189.1997. View

4.
Krajden M . Molecular detection of hepatitis C virus: impact of detection methodology on clinical and laboratory correlations. Crit Rev Clin Lab Sci. 1995; 32(1):41-66. DOI: 10.3109/10408369509084681. View

5.
Alter M, Margolis H, Krawczynski K, Judson F, Mares A, ALEXANDER W . The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327(27):1899-905. DOI: 10.1056/NEJM199212313272702. View